SATT Lutech signed an exclusive license agreement with Oncodiag this summer for the use of a molecular signature predictive of prostate cancer progression.
Oncodiag, a French company founded in 2013 and based in Miserey in Normandy, specializes in the development of diagnostic tools in the field of cancer, with a test already marketed for the diagnosis of bladder cancer (Urodiag®) and a another planned to be marketed in 2022 for colorectal cancer screening (Colodiag®). Oncodiag thus wishes to develop and offer a diagnostic test for prostate cancer making it possible to personalize patient management. This innovation was the subject of a patent application by SATT Lutech (Sorbonne University, AP-HP, Ligue contre le cancer, CeRePP, CHU de Tours, University of Tours and INSERM).
This discovery is the result of a collaboration between the team of Prof. Olivier Cussenot (APHP-Sorbonne University) and the CIT (Tumor Identity Cards) team of the National League Against Cancer, led by Aurélien de Reyniès. They were able to identify a molecular signature that can accurately determine whether the patient has slow-growing prostate cancer (cancer that will change little within 10 or 15 years of diagnosis). In fact, it is now estimated that more than 20% of patients with localized prostate cancer could benefit from regular monitoring rather than heavy treatment (prostatectomy) with side effects potentially more disabling than the disease itself. even. This therefore represents real progress in the diagnosis and management of this type of cancer